SomaLogic (NASDAQ:SLGC) versus CareCloud (NASDAQ:CCLDO) Head-To-Head Contrast

SomaLogic (NASDAQ:SLGC) and CareCloud (NASDAQ:CCLDO) are both business services companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Insider and Institutional Ownership

66.3% of SomaLogic shares are owned by institutional investors. 14.9% of SomaLogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SomaLogic and CareCloud’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SomaLogic	-139.23%	-25.49%	-22.27%
CareCloud	N/A	N/A	N/A

Valuation & Earnings

This table compares SomaLogic and CareCloud’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SomaLogic	$101.39 million	4.32	-$109.16 million	($0.75)	-3.11
CareCloud	$125.62 million	N/A	N/A	N/A	N/A

CareCloud has higher revenue and earnings than SomaLogic.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for SomaLogic and CareCloud, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SomaLogic	0	0	3	0	3.00
CareCloud	0	0	0	0	N/A

SomaLogic currently has a consensus target price of $6.75, suggesting a potential upside of 189.70%. Given SomaLogic’s higher possible upside, equities analysts plainly believe SomaLogic is more favorable than CareCloud.

About SomaLogic

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

About CareCloud

CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates in two segments, Healthcare IT and Medical Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.